A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects With Sjögren-Larsson Syndrome (SLS)

Trial Profile

A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects With Sjögren-Larsson Syndrome (SLS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Sjogren-Larsson syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 29 Apr 2018 According to an Aldeyra Therapeutics media release, results from part one of this trial are expected to be announced in 2019.
    • 29 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 02 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top